Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

With their help, we were able to identify a specific TMEM16F mutation which is common in Ashkenazi Jews in general ... new ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

Can a common parasite help treat Alzheimer’s? Scientists say Toxoplasma gondii may open pathways to brain therapies for ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev ... The most common ones include skin reactions where the injection ...

According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...

Designed for patients, caregivers, and anyone interested in Parkinson’s disease, this free event is open to the public with ...

According to the researchers, this mutation increases TMEM16F activity, which impacts how cells release substances from their membranes. The faulty alpha-synuclein is then picked up by nearby healthy ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...